X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

0.8039 (USD) • At close December 27, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q1
Revenue 0.560.56303.0600000000000000300003.5000000000
Cost of Revenue 0.2270.2680.0620.0620.5020.5160.5120.5010.4940.50.4990.4940.4910.4870.42000000000000000000.1
Gross Profit 0.3330.295-0.0622.998-0.502-0.516-0.512-0.501-0.494-0.5-0.499-0.494-0.491-0.487-0.42000300003.500000000-0.1
Gross Profit Ratio 0.5950.52400.9800000000000100100001000000000
Reseach & Development Expenses 19.17320.91419.79215.2119.08115.60115.60122.06319.01413.82114.11312.16213.18813.19312.10412.29811.3819.3428.9117.0658.5898.8545.6554.3449.5728.938.1339.2310.6013.9064.3914.2272.529
General & Administrative Expenses 000000014.41314.4136.7497.6647.1355.9315.8045.8325.3575.5995.3164.673.9144.3834.564.7838.6283.2753.6862.8172.3762.4551.7381.4361.4730
Selling & Marketing Expenses 0000000-7.172-7.85000000000000000000000000
SG&A 15.6613.27817.4359.9278.13310.20410.2047.2416.5636.7497.6647.1355.9315.8045.8325.3575.5995.3164.673.9144.3834.564.7838.6283.2753.6862.8172.3762.4551.7381.4361.4731.24
Other Expenses 000.1050.2120.017-29.892-29.8925.288-3.513-0.0590.06-1.149-0.074-0.6350.186-0.7450.228-0.4860.0410.0380.0520.1490-0.006-0.0060.001-0.074-0.0730.086-0.028-0.0010.0160
Operating Expenses 34.83333.99837.22725.13727.21425.80525.80529.30425.57720.5721.77719.29719.11918.99717.93617.65516.9814.65813.58110.97912.97213.41410.43812.7710.83112.110.50510.91811.4384.7825.1275.1393.769
Operating Income -34.571.103-37.289-25.199-27.214-25.805-25.805-22.907-25.577-20.57-21.268-29.055-19.119-18.997-17.936-17.655-16.98-14.658-10.581-10.875-16.976-13.414-10.438-9.472-12.847-12.616-10.95-11.606-13.056-5.644-5.827-5.7-3.869
Operating Income Ratio -61.607126.2930-8.23500000000000-5,885,000,000,00000-3.5270000-2.706000000000
Total Other Income Expenses Net -2.18119.748-14.4586.10224.935-29.8925.288-3.513-1.445-0.638-0.674-1.149-1.054-0.635-0.734-0.745-0.469-0.486-0.4090.038-0.7380.031-0.4350.1141.9470.4830.320.4191.456-0.0610.4420.3790.369
Income Before Tax -36.68190.851-51.747-19.097-2.279-55.697-55.697-24.016-29.09-21.208-21.942-30.204-20.173-19.632-18.67-18.4-17.449-15.144-10.99-10.837-17.714-13.383-10.873-9.358-10.9-12.133-10.63-11.187-11.6-5.705-5.385-5.321-3.5
Income Before Tax Ratio -65.502161.3690-6.24100000000000-6,133,333,333,333.33300-3.6630000-2.674000000000
Income Tax Expense 0.0150.0180.0190.0330.0260.0150.0150.0040.0140.0040.0230.0030.0020.0060.00600.925-0.0660.148-0.1360.740.6610.3990.2480.2530.260.1930.2430.4290.4161.0180.8080
Net Income -36.69690.833-51.766-19.13-2.305-55.712-55.712-24.02-29.104-21.212-21.965-30.207-20.175-19.638-18.676-18.4-17.449-15.144-11.138-10.837-17.714-13.383-10.873-9.358-10.9-12.133-10.63-11.187-11.6-5.705-5.385-5.321-3.5
Net Income Ratio -65.529161.3370-6.25200000000000-6,133,333,333,333.33300-3.7130000-2.674000000000
EPS -0.180.45-0.26-0.096-0.012-0.33-0.38-0.24-0.29-0.6-0.65-1.04-0.76-0.74-0.9-0.91-0.87-0.76-0.56-0.66-1.22-1.02-6.33-5.45-4.57-5.09-4.46-10.09-6.43-6.15-5.8-5.73-8.81
EPS Diluted -0.180.45-0.26-0.096-0.012-0.33-0.38-0.24-0.29-0.6-0.65-1.04-0.76-0.74-0.9-0.91-0.87-0.76-0.56-0.66-1.22-1.02-6.33-5.45-4.57-5.09-4.46-10.09-6.43-6.15-5.8-5.73-8.81
EBITDA -34-33.703-49.811-17.149-0.143-54.033-22.395-27.445-20.154-19.79-20.53-28.785-19.059-18.24-17.359-17.552-16.834-14.391-10.37-10.104-16.999-12.847-10.454-9.07-10.605-11.835-10.317-10.772-11.295-5.213-4.318-4.479-3.769
EBITDA Ratio -60.714-59.8630-8.21500000000000-5,885,000,000,00000-3.4030000-2.591000000000